Timing of newborn hearing screening in the neonatal intensive care unit: implications for targeted screening for congenital cytomegalovirus infection

Medoro, Alexandra K; Malhotra, Prashant S.; Shimamura, Masako; Findlen, Ursula M; Gerth, Holly; Hounam, Gina; Salamon, Douglas; Foor, Nicholas; Hanlon, Cory T; Leber, Amy; Adunka, Oliver F.; Sánchez, Pablo J.

doi:10.1038/s41372-020-00801-0

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum CMV IgM is not recommended as both false negative (>30%) and false-positive (>10%) results occur. Importantly, viral detection in the first 21 days of age is required to diagnose in-utero infection [56]. After 3 weeks of age, congenital infection is unable to be differentiated from CMV acquired by passage through the birth canal of seropositive women who are shedding CMV in cervical/vaginal secretions at delivery, breastfeeding (a common source), or contact with other infected children and caregivers [12,13,46].…”

Section: Congenital CMV Infection Classificationmentioning

confidence: 99%

“Minimally symptomatic” congenital cytomegalovirus infection: latest data and emerging concepts

Howard,

Nishikawa,

Sánchez

2024

Current Opinion in Pediatrics

Self Cite

View full text Add to dashboard Cite

Purpose of review Universal and targeted screening of newborns for congenital cytomegalovirus (CMV) infection is increasing globally. Questions remain concerning the management of infants who have been identified with congenital CMV infection, especially those with “minimally symptomatic” or clinically inapparent infection. Our objective is to discuss current management of CMV-infected neonates with a focus on less affected infants with or without sensorineural hearing loss (SNHL). Recent findings Valganciclovir is being prescribed increasingly in neonates with congenital CMV infection for improvement in hearing outcomes through 2 years of age. Treatment initiated in the first month of age is recommended for clinically apparent disease. A recent study showed hearing improvement at 18–22 months of age when therapy was initiated at age 1–3 months in infants with clinically inapparent CMV infection and isolated SNHL. Summary Antiviral therapy with either ganciclovir or valganciclovir has shown moderate benefit in prevention of hearing deterioration among infants with clinically apparent CMV infection or isolated SNHL. Sustainability of benefit beyond 2 years of age remains unknown. At present, infants with clinically inapparent CMV infection (normal complete evaluation including hearing) should not receive antiviral therapy. All CMV-infected infants require close audiological and neurodevelopmental follow-up.

show abstract

Section: Congenital CMV Infection Classificationmentioning

confidence: 99%

“Minimally symptomatic” congenital cytomegalovirus infection: latest data and emerging concepts

Howard,

Nishikawa,

Sánchez

2024

Current Opinion in Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

Congenital Cytomegalovirus Infection and Hearing Loss: It’s Time to Screen

Nishikawa,

Sánchez

2024

Otol Neurotol

View full text Add to dashboard Cite

Congenital CMV infection is the leading nongenetic cause of sensorineural hearing loss worldwide, yet most parents have never heard of it. The majority of infected newborns have no clinical signs of infection, although a substantial proportion may have hearing loss at birth or develop it later in life. As antiviral treatment with ganciclovir or valganciclovir initiated in the first month of age improves audiologic outcomes, there is an urgent need for timely identification of infected neonates. A targeted approach that tests neonates who refer on the newborn hearing screen has been implemented in many states and hospital programs, but it fails to identify about 40% of children who experience CMV-related hearing loss. A universal screening approach is optimal given the prevalence of congenital CMV infection, its associated sequelae, the availability of a simple saliva screening tool, the available antiviral treatment, and the directed therapies for hearing impairment.

show abstract

Timing of newborn hearing screening in the neonatal intensive care unit: implications for targeted screening for congenital cytomegalovirus infection

Cited by 2 publications

References 32 publications

“Minimally symptomatic” congenital cytomegalovirus infection: latest data and emerging concepts

“Minimally symptomatic” congenital cytomegalovirus infection: latest data and emerging concepts

Congenital Cytomegalovirus Infection and Hearing Loss: It’s Time to Screen

Contact Info

Product

Resources

About